Nadine Loefflad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nadine Loefflad has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Elisa Menozzi
Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK
4 shared publications - Anthony Henry Vernon Schapira
Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK
3 shared publications - Roxana Mezabrovschi
Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK
3 shared publications - Sara Lucas Del Pozo
Department of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London (UCL), London, UK
3 shared publications - Selen Yalkic
Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK
3 shared publications - Sofia Koletsi
Anthony schapira UCL University College London University of London
3 shared publications
Latest Publications
- Open Access
- 22 January 2026
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 16 (2) , 258-265
Serum phosphorylated tau 217 in GBA1 variant carriers with and without Parkinson disease
It is unclear whether Alzheimer disease pathology drives cognitive decline in Parkinson disease (PD) patients carrying GBA1 variants. We evaluated levels of serum phosphorylated tau 217 (p-tau217) in samples from 29 GBA1 -PD, 32 idiopathic PD, 20 non-manifesting GBA1 variant carriers ( GBA1 -NMC) and 31 healthy controls. No differences were detected between PD groups. GBA1 -NMCs showed higher levels than healthy controls, which correlated to worse cognition and subthreshold parkinsonism. Serum p-tau217 is not a marker of cognitive decline in GBA1 -PD. Whether p-tau217 levels in GBA1 -NMCs can predict conversion to PD or are a marker of cognitive decline, irrespective of PD, remains unknown.
- 22 January 2026
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 16 (2) , 258-265
Open AccessSerum phosphorylated tau 217 in GBA1 variant carriers with and without Parkinson disease
It is unclear whether Alzheimer disease pathology drives cognitive decline in Parkinson disease (PD) patients carrying GBA1 variants. We evaluated levels of serum phosphorylated tau 217 (p-tau217) in samples from 29 GBA1 -PD, 32 idiopathic PD, 20 non-manifesting GBA1 variant carriers ( GBA1 -NMC) and 31 healthy controls. No differences were detected between PD groups. GBA1 -NMCs showed higher levels than healthy controls, which correlated to worse cognition and subthreshold parkinsonism. Serum p-tau217 is not a marker of cognitive decline in GBA1 -PD. Whether p-tau217 levels in GBA1 -NMCs can predict conversion to PD or are a marker of cognitive decline, irrespective of PD, remains unknown.
- Open Access
- 1 October 2025
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 11 (1) , 1-6
Severe GBA1 variants drive the GBA1-PD clinical phenotype: implications for counselling and clinical trials
Variants in the GBA1 gene are the commonest genetic risk factor for Parkinson disease (PD). Genotype-phenotype correlations exist but with conflicting data. Here, we compared the clinical phenotype of 183 idiopathic PD (iPD) patients, 39 severe GBA1-PD, 24 mild GBA1-PD, and 55 risk GBA1-PD. Compared to iPD, we observed that only severe GBA1-PD patients had a distinctive, more several clinical profile, characterised by worse depression, hyposmia, cognitive dysfunction, and possibly constipation.
- 1 October 2025
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 11 (1) , 1-6
Open AccessSevere GBA1 variants drive the GBA1-PD clinical phenotype: implications for counselling and clinical trials
Variants in the GBA1 gene are the commonest genetic risk factor for Parkinson disease (PD). Genotype-phenotype correlations exist but with conflicting data. Here, we compared the clinical phenotype of 183 idiopathic PD (iPD) patients, 39 severe GBA1-PD, 24 mild GBA1-PD, and 55 risk GBA1-PD. Compared to iPD, we observed that only severe GBA1-PD patients had a distinctive, more several clinical profile, characterised by worse depression, hyposmia, cognitive dysfunction, and possibly constipation.
- Open Access
Microbiome signature of Parkinson disease in healthy and genetically at-risk individuals
Summary: Parkinson disease (PD) is a major cause of disability with significant personal and system financial implications 1,2 . GBA1 variants are the commonest genetic risk factor for PD and increase the risk up to 30-fold 3,4 . Why only ∼20% of GBA1 variant carriers develop PD remains unknown. Here, by combining clinical and faecal metagenomics data from PD individuals carrying or not GBA1 variants, carriers of GBA1 variants not manifesting PD symptoms (GBA-NMC) and healthy controls, and using an innovative microbiome analysis, we show that a large component of the gut microbiome evolves from healthy across GBA-NMC towards PD and is strongly correlated with disease progression in patients, and prodromal symptoms suggestive of future development of PD in GBA-NMC. By using species altered in PD and GBA-NMC, we detect healthy individuals with the strongest prodromal PD clinical profile. These findings indicate that gut microbiome alterations can identify individuals with GBA1 variants most prone to develop PD and individuals in the general population that may be progressing towards PD. Healthy nutrition mitigates microbiome alterations associated with disease severity, suggesting that it could modify disease progression in PD patients and decrease the risk of disease development in healthy individuals including those with GBA1 variants.
Open AccessMicrobiome signature of Parkinson disease in healthy and genetically at-risk individuals
Summary: Parkinson disease (PD) is a major cause of disability with significant personal and system financial implications 1,2 . GBA1 variants are the commonest genetic risk factor for PD and increase the risk up to 30-fold 3,4 . Why only ∼20% of GBA1 variant carriers develop PD remains unknown. Here, by combining clinical and faecal metagenomics data from PD individuals carrying or not GBA1 variants, carriers of GBA1 variants not manifesting PD symptoms (GBA-NMC) and healthy controls, and using an innovative microbiome analysis, we show that a large component of the gut microbiome evolves from healthy across GBA-NMC towards PD and is strongly correlated with disease progression in patients, and prodromal symptoms suggestive of future development of PD in GBA-NMC. By using species altered in PD and GBA-NMC, we detect healthy individuals with the strongest prodromal PD clinical profile. These findings indicate that gut microbiome alterations can identify individuals with GBA1 variants most prone to develop PD and individuals in the general population that may be progressing towards PD. Healthy nutrition mitigates microbiome alterations associated with disease severity, suggesting that it could modify disease progression in PD patients and decrease the risk of disease development in healthy individuals including those with GBA1 variants.
- Open Access
Phenotypic effect of GBA1 variants in individuals with and without Parkinson disease: the RAPSODI study
Background: Variants in the GBA1 gene cause the lysosomal storage disorder Gaucher disease (GD). They are also risk factors for Parkinson disease (PD), and modify the expression of the PD phenotype. The penetrance of GBA1 variants in PD is incomplete, and the ability to determine who amongst GBA1 variant carriers are at higher risk of developing PD, would represent an advantage for prognostic and trial design purposes. Objectives: To compare the motor and non-motor phenotype of GBA1 carriers and non-carriers. Methods: We present the cross-sectional results of the baseline assessment from the RAPSODI study, an online assessment tool for PD patients and GBA1 variant carriers. The assessment includes clinically validated questionnaires, a tap-test, the University of Pennsyllvania Smell Identification Test and cognitive tests. Additional, homogeneous data from the PREDICT-PD cohort were included. Results: A total of 379 participants completed all parts of the RAPSODI assessment (89 GBA1 -negative controls, 169 GBA1 -negative PD, 47 GBA1 -positive PD, 47 non-affected GBA1 carriers, 27 GD). Eightysix participants were were recruited through PREDICT-PD (43 non-affected GBA1 carriers and 43 GBA1 -negative controls). GBA1 -positive PD showed worse performance in visual cognitive tasks and olfaction compared to GBA1 -negative PD patients. No differences were detected between non-affected GBA1 carriers carriers and GBA1 -negative controls. No phenotypic differences were observed between any of the non-PD groups. Conclusions: Our results support previous evidence that GBA1 -positive PD has a specific phenotype with more severe non-motor symptoms. However, we did not reproduce previous findings of more frequent prodromal PD signs in non-affected GBA1 carriers.
Open AccessPhenotypic effect of GBA1 variants in individuals with and without Parkinson disease: the RAPSODI study
Background: Variants in the GBA1 gene cause the lysosomal storage disorder Gaucher disease (GD). They are also risk factors for Parkinson disease (PD), and modify the expression of the PD phenotype. The penetrance of GBA1 variants in PD is incomplete, and the ability to determine who amongst GBA1 variant carriers are at higher risk of developing PD, would represent an advantage for prognostic and trial design purposes. Objectives: To compare the motor and non-motor phenotype of GBA1 carriers and non-carriers. Methods: We present the cross-sectional results of the baseline assessment from the RAPSODI study, an online assessment tool for PD patients and GBA1 variant carriers. The assessment includes clinically validated questionnaires, a tap-test, the University of Pennsyllvania Smell Identification Test and cognitive tests. Additional, homogeneous data from the PREDICT-PD cohort were included. Results: A total of 379 participants completed all parts of the RAPSODI assessment (89 GBA1 -negative controls, 169 GBA1 -negative PD, 47 GBA1 -positive PD, 47 non-affected GBA1 carriers, 27 GD). Eightysix participants were were recruited through PREDICT-PD (43 non-affected GBA1 carriers and 43 GBA1 -negative controls). GBA1 -positive PD showed worse performance in visual cognitive tasks and olfaction compared to GBA1 -negative PD patients. No differences were detected between non-affected GBA1 carriers carriers and GBA1 -negative controls. No phenotypic differences were observed between any of the non-PD groups. Conclusions: Our results support previous evidence that GBA1 -positive PD has a specific phenotype with more severe non-motor symptoms. However, we did not reproduce previous findings of more frequent prodromal PD signs in non-affected GBA1 carriers.